• Home
  • NEW DAY MEDICINE
  • 7(45)2022
  • 76 -7 (45) 2022 — Nishanov M.F., Akbarov F.S., — PREVALENCE OF REFLUX ESOPHAGITIS AND RISK FACTORS FOR THEIR DEVELOPMENT

76 -7 (45) 2022 — Nishanov M.F., Akbarov F.S., — PREVALENCE OF REFLUX ESOPHAGITIS AND RISK FACTORS FOR THEIR DEVELOPMENT

PREVALENCE OF REFLUX ESOPHAGITIS AND RISK FACTORS FOR THEIR DEVELOPMENT

Nishanov M.F., Andijan State Medical Institute, Uzbekistan

Akbarov F.S., Andijan State Medical Institute, Uzbekistan

 Nosirov M.M. Andijan State Medical Institute, Uzbekistan

Resume

The authors analyze prognostic risk factors for the development of reflux esophagitis (RE). The authors conclude that the main risk factors against which RE was detected were obesity, stress, smoking hiatal hernia (HH), cardiac insufficiency (NFC), medication, and alimentary factor. In their presence, the frequency of EC development reached 44.6-71.4% of cases (in the presence of a factor), while in the absence of these factors, esophagitis was detected much less frequently – 15.7-28.7% of cases.

Keywords: reflux esophagitis, endoscopy, gastroesophageal reflux disease, GERD, risk factors.

First page

402

Last page

406

For citation: Nishanov M.F., Akbarov F.S., Nosirov M.M. PREVALENCE OF REFLUX ESOPHAGITIS AND RISK FACTORS FOR THEIR DEVELOPMENT //New Day in Medicine 7(45)2022 402-406 https://clck.ru/sUQ6m

LIST OF REFERENCES:

  1. Евсютина Ю.В. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы / Ю.В. Евсютина, А.С. Трухманов // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. – 2014. – № 5. – С. 4-9.
  2. Лазебник Л.Б., Бордин Д.С., Машарова А.А. Длительная терапия ингибиторами протонной помпы: баланс пользы и рисков // Экспериментальная и клиническая гастроэнтерология. – 2010. – №9. – С. 3-8.
  3. Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г. Клиническая эффективность рабепразола. // Медицинский алфавит, 2017, 9(306): 40-46.
  4. Рыжкова О.В. Гастроэзофагеальная рефлюксная болезнь: учебное пособие. – Иркутск: ИГМУ, 2020. – 64 с.
  5. Шульпекова Ю.О. Гастроэзофагеальная рефлюксная болезнь: клинические и фармакологические аспекты / Ю.О. Шульпекова, В.Т. Ивашкин // Русский мед. журн. – 2002. – № 4. – С. 200-205.
  6. Gong E.J., Park C.H., Jung D.H., Kang S.H., Lee J.Y., Lim H., Kim D.H. Endoscopic Therapy And Instrument Research Group Under The Korean Society Of Neurogastroenterology And Motility. Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis. // J Pers Med. 2022 Apr 12;12(4):621. doi: 10.3390/jpm12040621.
  7. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. // Am J Gastroenterol. 2013;108:308-328.
  8. Lundell L., Miettinen P., Myrvold H.E., Hatlebakk J.G., Wallin L., Engström C., Julkunen R., Montgomery M., Malm A., Lind T., Walan A; Nordic GERD Study Group. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1292-8; quiz 1260. doi: 10.1016/j.cgh.2009.05.021.
  9. Richter J.E., Rubenstein J.H. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018; 154:267-276. doi:10.1053/j.gastro.2017.07.045. 
  10. Sifrim D., Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012; 61: 1340-1354.

file

download